We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

The reason Novo Nordisk is losing patent protection is because it wouldn't pay a couple hundred bucks. In 2019, the Canadian patent office sent a letter saying it hadn't received Novo Nordisk's annual ...

Tensions in the Middle East shake Wall Street as healthcare stocks surge. Discover top gainers, Novo Nordisk's moves, and big pharma M&A updates.

Novo Nordisk A/S (NYSE:NVO) is one of the 17 stocks that Jim Cramer commented on. During the episode, Cramer said that he ...

Novo Nordisk, the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company after a year of decline that ultimately led to the firing of its CEO last ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

PETALING JAYA: Nova Pharma Solutions Bhd (NPS) has accepted a letter of acceptance from the National Institutes of Biotechnology Malaysia (NIBM) to undertake equipment procurement and facility ...

Scotiabank initiated coverage of UroGen Pharma (URGN) with an Outperform rating and $23 price target The company is developing a novel treatment for nonmuscle invasive bladder cancer, which the fi ...

The new model, called Nova Act, is designed to help developers build agents, or AI software that can complete multi-step tasks for users without supervision. Amazon showed Nova Act searching for ...

But some scientists and the food industry have said Nova is too simple ... Maggie is a Britain-based reporter covering the European pharmaceuticals industry with a global perspective.

EXCLUSIVE: Marvel Television has paused development on three projects: Nova, Strange Academy and Terror, Inc. Sources stressed to Deadline that these projects were never officially greenlit ...

Lead program is Phase 1/2 trial of Nova Pharmaceutical’s Clinical Stage Nitric Oxide Synthase (NOS) Inhibitor on top of standard-of-care nab-paclitaxel and alpelisib in metaplastic breast cancer.